What’s in the stick.
NEBODE Foundation contains four ingredients. No proprietary blends, no hidden doses. This page explains what each ingredient is, why we included it, and where the supporting evidence comes from.
The Foundation Architecture
Four pathways, designed to work as one daily system.
Creatine monohydrate and the phosphocreatine energy system.
TMG / betaine and methyl-donor activity.
Live cultures selected for the Foundation’s digestive-function focus.
Sodium, potassium and magnesium as the Foundation’s mineral base.
This is NEBŌDE’s current formulation framework. It explains how the ingredients are organised; it does not claim that the complete Foundation has been clinically tested or produces a combined health outcome.
Ingredients & Evidence
Energy — Creatine Monohydrate
Creatine Monohydrate
Creatine is involved in the phosphocreatine energy system used to regenerate ATP. Human research has examined creatine in relation to muscle function and exercise, with other research areas requiring careful interpretation by population, dose and study design. The 5g figure is a current development specification, not a final label confirmation. The complete NEBŌDE Foundation has not been clinically tested.
Reference: [1][2]
Metabolism — TMG / Betaine
Betaine / Trimethylglycine — final form TBC
TMG, also known as betaine, functions as an osmolyte and methyl donor. Betaine has an authorised nutrition claim relating to normal homocysteine metabolism when the relevant conditions are met. Final form, dose, label wording and UK claim review remain to be confirmed. The 1.5g figure is a current development specification.
Reference: [3]
Hydration — Electrolytes
Sodium, potassium and magnesium salts — final forms TBC
Electrolytes are minerals supplied here as sodium, potassium and magnesium salts. Their permitted nutrition wording depends on the final mineral forms and amounts present in a serving. The final blend, dose and label wording will be confirmed after formulation and UK review. This is a development specification, not a completed product label.
Digestion — Live Cultures
Bacillus coagulans — final strain and specification TBC
Bacillus coagulans is a spore-forming live culture. The final strain, formulation, stability profile and whether the CFU quantity is guaranteed through end of shelf life must be confirmed with the manufacturer. The 2 billion CFU figure is a current development target. UK consumer wording remains subject to claims review; this page does not make a specific gut-health outcome claim.
Quality & Testing
Before launch, the finished product will require documented checks for identity, purity, safety and stability. The checks described on this page are planned requirements, not completed testing.
Ingredient identity, purity and specification checks before manufacture.
Microbial, contaminant and heavy-metal testing where applicable to the final materials.
Shelf-life testing to establish how the finished stick performs through its intended life.
CFU verification at the relevant point in shelf life, not only at manufacture.
How to Read the Evidence
Research on an individual ingredient does not prove that the complete NEBŌDE Foundation produces the same result. Final doses, forms, strain, shelf-life data and UK wording must be confirmed before launch. NEBŌDE does not make treatment or disease claims, and this page is not medical advice.
References
References below correspond to published research and official guidance. NEBŌDE does not claim these sources prove the complete Foundation delivers equivalent outcomes.
- [1] Rawson, E.S. & Volek, J.S. (2003). Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Journal of Strength and Conditioning Research, 17(4), 822–831.
- [2] EFSA Panel on Dietetic Products, Nutrition and Allergies (2011). Scientific Opinion on the substantiation of health claims related to creatine. EFSA Journal, 9(7), 2303. doi:10.2903/j.efsa.2011.2303
- [3] Olthof, M.R. & Verhoef, P. (2005). Effects of betaine intake on plasma homocysteine concentrations and consequences for health. Current Drug Metabolism, 6(1), 15–22.
NEBŌDE Foundation is currently in pre-production development. Final formulation, ingredient specifications, labelling and permitted consumer claims will be confirmed before launch following appropriate UK regulatory review. This page is for general information and does not constitute medical advice.